A novel splice variant of HER2 with increased transformation activity

Molecular Carcinogenesis

Volumn 23, Issue 2, 1998, Pages 62-68

  Kwong, Ka Yin ^a   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Alternative splicing; HER2; Proto oncogene; Receptor protein tyrosine kinase; Transformation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NEUROBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS;

3T3 CELLS; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; CHO CELLS; COS CELLS; CRICETINAE; DNA, COMPLEMENTARY; HUMANS; MICE; MOLECULAR SEQUENCE DATA; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; TUMOR CELLS, CULTURED;

EID: 0001889163     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O     Document Type: Article

References (21)

1. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophy Acta 1198:165-184, 1994.
2. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649-657, 1986.
3. Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 8:5570-5574, 1988.
4. Lemoine NR, Staddon S, Dickson C, Barnes DM, Gullick WJ. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene 5:237-239, 1990.
5. Sachse R, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. Absence of activating mutations in the transmembrane domain of the c-erbB-2 protooncogene in human lung cancer. Jpn J Cancer Res 83:1299-1303, 1992.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987.
7. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989.
8. Park JB, Rhim JS, Park SC, Kimm SW, Kraus MH. Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res 49:6605-6609, 1989.
9. Xia W, Lau YK, Zhang HZ, et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 3:3-9, 1997.
10. Weiner DB, Nordberg J, Robinson R, et al. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 50:421-425, 1990.
11. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/ 3T3 cells. Science 237:178-182, 1987.
12. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159-7163, 1987.
13. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578-10582, 1992.
14. Siegel PM, Dankort DL, Hardy WR, Muller WJ. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14:7068-7077, 1994.
15. 15: Khosravi-Far R, White MA, Westwick JK, et al. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol 16:3923-3933, 1996.
16. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: Causes and consequences. Hum Genet 90:41-54, 1992.
17. Bargmann CI, Weinberg RA. Oncogenic activation of the neuencoded receptor protein by point mutation and deletion. EMBO J 7:2043-2052, 1988.
18. Siegel PM, Muller WJ. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc Natl Acad Sci USA 93:8878-8883, 1996.
19. Scott GK, Robles R, Park JW, et al. A truncated intracellular HER2/ neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 13:2247-2257, 1993.
20. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394-398, 1995.
21. Kokai Y, Cohen JA, Drebin JA, Greene MI. Stage-and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci USA 84:8498-8501, 1987.